PDF
ePub
Citation
Print
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by synovitis and joint damage. The etiology of RA is multi-factorial including various genetic and environmental factors, and the pathogenesis is complex involving lymphocyte infiltration, synovial cell proliferation, pannus formation, and cartilage and bone destruction. Various animal models have been used to study potential etiopathogenetic mechanisms in RA. They are also extensively used to test new potential therapeutic agents. Despite some limitations, those animal models have significantly progressed our understanding of the basic mechanisms and have contributed to several current major advances in the treatment of RA. These models include the induced arthritis models such as collagen-induced arthritis (CIA), antibody-induced arthritis, the genetically manipulated or spontaneous arthritis models, and humanized mouse models. The choice regarding the proper model should be performed carefully, taking into account the biology of the animal model and the therapeutic target under evaluation in order to make better predictions of efficacy in human RA. Thus, in this review, we describe important mouse models of RA, focusing on the underlying mechanisms, methods, advantages and limitations, and usefulness.
Figures and Tables
References
1. Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis. 2008. 67:1505–1515.
2. Kollias G, Papadaki P, Apparailly F, Vervoordeldonk MJ, Holmdahl R, Baumans V, et al. Animal models for arthritis: innovative tools for prevention and treatment. Ann Rheum Dis. 2011. 70:1357–1362.
3. van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/ European League Against Rheumatism criteria. Arthritis Rheum. 2011. 63:37–42.
4. de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford). 2012. 51:1610–1617.
5. van den Berg WB. Lessons from animal models of arthritis over the past decade. Arthritis Res Ther. 2009. 11:250.
6. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med. 1977. 146:857–868.
7. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007. 7:118–130.
8. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol. 2003. 25:3–18.
9. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med. 1981. 154:688–700.
10. Inglis JJ, Criado G, Medghalchi M, Andrews M, Sandison A, Feldmann M, et al. Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. Arthritis Res Ther. 2007. 9:R113.
11. Youn J. Lessons for the pathogenesis of rheumatoid arthritis acquired from experimental animal models. Hanyang Med Rev. 2005. 25:53–66.
12. Protocol for the Successful Induction of Collagen-Induced Arthritis (CIA) and Collagen Antibody-Induced Arthritis (CAIA) in Mice. 2009. Redmond, chondrex: Reagents & Consulting for Inflammatory Research, Redmond.
13. Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007. 2:1269–1275.
14. Hah YS, Lee YR, Jun JS, Lim HS, Kim HO, Jeong YG, et al. A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis. Arthritis Rheum. 2010. 62:2313–2321.
15. Lamacchia C, Palmer G, Seemayer CA, Talabot-Ayer D, Gabay C. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum. 2010. 62:452–462.
16. Campbell IK, Hamilton JA, Wicks IP. Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol. 2000. 30:1568–1575.
17. Boross P, van Lent PL, Martin-Ramirez J, van der Kaa J, Mulder MH, Claassens JW, et al. Destructive arthritis in the absence of both FcgammaRI and FcgammaRIII. J Immunol. 2008. 180:5083–5091.
18. Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One. 2008. 3:e2267.
19. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009. 60:390–395.
20. Inglis JJ, Simelyte E, McCann FE, Criado G, Williams RO. Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc. 2008. 3:612–618.
21. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 1996. 87:811–822.
22. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999. 10:451–461.
23. Schaller M, Burton DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol. 2001. 2:746–753.
24. Maccioni M, Zeder-Lutz G, Huang H, Ebel C, Gerber P, Hergueux J, et al. Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med. 2002. 195:1071–1077.
25. Monach P, Hattori K, Huang H, Hyatt E, Morse J, Nguyen L, et al. The K/BxN mouse model of inflammatory arthritis: theory and practice. Methods Mol Med. 2007. 136:269–282.
26. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991. 10:4025–4031.
27. van den Berg WB. Lessons from animal models of arthritis over the past decade. Arthritis Res Ther. 2009. 11:250.
28. Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, et al. Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest. 2001. 107:1127–1135.
29. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000. 191:313–320.
30. Cope Andrew P.. Arthritis Research: Volume 2: Methods and Protocols (Methods in Molecular Medicine). 2007. Totowa, New Jersey: Human press;215–223.
31. Holmdahl R, Rubin K, Klareskog L, Larsson E, Wigzell H. Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum. 1986. 29:400–410.
32. Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol. 2003. 163:1827–1837.
33. Jacobs JP, Pettit AR, Shinohara ML, Jansson M, Cantor H, Gravallese EM, et al. Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis Rheum. 2004. 50:2685–2694.
34. Kyburz D, Corr M. The KRN mouse model of inflammatory arthritis. Springer Semin Immunopathol. 2003. 25:79–90.
35. Lee SI, Boyle DL, Berdeja A, Firestein GS. Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-Terminal kinase pathway. Arthritis Res Ther. 2012. 14:R38.
36. Gregersen JW, Holmes S, Fugger L. Humanized animal models for autoimmune diseases. Tissue Antigens. 2004. 63:383–394.
37. Taneja V, Behrens M, Mangalam A, Griffiths MM, Luthra HS, David CS. New humanized HLA-DR4-transgenic mice that mimic the sex bias of rheumatoid arthritis. Arthritis Rheum. 2007. 56:69–78.
38. Barry TS, Haynes BF. In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice. J Clin Immunol. 1992. 12:311–324.
39. Davis LS, Sackler M, Brezinschek RI, Lightfoot E, Bailey JL, Oppenheimer-Marks N, et al. Inflammation, immune reactivity, and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis. Am J Pathol. 2002. 160:357–367.
40. Pearson T, Greiner DL, Shultz LD. Creation of "humanized" mice to study human immunity. Curr Protoc Immunol. 2008. Chapter 1:Unit 15.21.
41. Whitehouse MW. Adjuvant arthritis 50 years on: The impact of the 1956 article by C. M. Pearson, 'Development of arthritis, periarthritis and periostitis in rats given adjuvants'. Inflamm Res. 2007. 56:133–138.
42. Holmdahl R, Lorentzen JC, Lu S, Olofsson P, Wester L, Holmberg J, et al. Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev. 2001. 184:184–202.
43. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther. 2005. 7:R458–R467.
44. Vossenaar ER, Nijenhuis S, Helsen MM, van der Heijden A, Senshu T, van den Berg WB, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum. 2003. 48:2489–2500.
45. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med. 2008. 205:967–979.
XML Download